ImmunityBio (IBRX) Notes Payables (2014 - 2023)

ImmunityBio (IBRX) has 5 years of Notes Payables data on file, last reported at $481.9 million in Q2 2023.

• Notes Payables for Q2 2023 came in at $481.9 million, up 60.59% year-over-year; the trailing twelve-month figure through Jun 2023 was $481.9 million (up 60.59% YoY), and the FY2022 annual result was $431.9 million, up 44.33% from the prior year.
• Notes Payables climbed to $481.9 million in Q2 2023 per IBRX's latest filing, from $29.9 million in the prior quarter.
• Over five years, Notes Payables peaked at $481.9 million in Q2 2023 and troughed at $29.9 million in Q1 2023.
• A 3-year average of $307.1 million and a median of $299.8 million in 2022 frame the typical range for Notes Payables.
• On a YoY basis, Notes Payables climbed as much as 60.59% in 2023 and fell as far as 90.02% in 2023.
• A 3-year view of Notes Payables shows it stood at $299.2 million in 2021, then soared by 44.33% to $431.9 million in 2022, then advanced by 11.58% to $481.9 million in 2023.
• Business Quant data shows IBRX's Notes Payables at $481.9 million in Q2 2023, $29.9 million in Q1 2023, and $431.9 million in Q4 2022.